UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: January 7, 2016
(*Date of earliest event reported*)

CELLECTAR BIOSCIENCES, INC.
(*Exact name of registrant as specified in its charter*)

Delaware	**1-36598**	**04-3321804**
(State or other jurisdiction of incorporation)	*(Commission File Number)*	*(IRS Employer Identification Number)*

3301 Agriculture Drive
Madison, WI 53716
(*Address of principal executive offices*)

(608) 441-8120
(*Registrant's telephone number, including area code*)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01 REGULATION FD DISCLOSURE

On January 7, 2016, we issued a press release announcing that our CEO, Jim Caruso, will be presenting at the Biotech Showcase in San Francisco on January 12, 2016 at 5:00 PM PT in the Mission I room. A copy of the press release, and the Corporate Presentation to be used, are furnished as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Number	Title
99.1	Press release dated January 7, 2016, entitled "Cellectar Biosciences to Present at the 2016 Biotech Showcase"
99.2	Cellectar Biosciences, Inc. Corporate Presentation, dated January 11, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 11, 2016

CELLECTAR BIOSCIENCES, INC.

By: */s/ Chad J. Kolean*
Name: Chad J. Kolean
Title: Vice President and Chief Financial Officer

EXHIBIT INDEX

Number	Title
99.1	Press release dated January 7, 2016, entitled “Cellectar Biosciences to Present at the 2016 Biotech Showcase”
99.2	Cellectar Biosciences, Inc. Corporate Presentation, dated January 11, 2016

Exhibit 99.1

Cellectar Biosciences to Present at the 2016 Biotech Showcase

Madison, WI (January 7, 2016) — Cellectar Biosciences, Inc. (NASDAQ:CLRB), an oncology-focused biotechnology company, announces today its CEO, Jim Caruso, will be presenting at the Biotech Showcase in San Francisco on January 12, 2016 at 5:00 PM PT in the Mission I room.

“The Biotech Showcase is an important industry gathering, uniting a unique combination of established and emerging company participants with a diverse group of investors,” said Mr. Caruso. “With our recent announcements regarding the successful advancement of our multiple myeloma program and initial corporate collaboration to research a series of chemotherapeutics in combination with our PDC delivery platform, we welcome the opportunity for Cellectar to further update the investment community on our continued progress.”

Following the presentation, a link to the latest presentation, including both slides and audio, will be posted on the company’s website.

About Cellectar Biosciences, Inc.
Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar's PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The Company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated Phase 1 study in patients with relapsed or refractory multiple myeloma. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1603-PTX), a preclinical stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For additional information please visit www.cellectarbiosciences.com.

# # #

This news release contains forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2014. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

INVESTOR AND MEDIA CONTACT:
Jules Abraham
JQA Partners
917-885-7378
jabraham@jqapartners.com

Exhibit 99.2

NASDAQ: CLRB

January 11, 2016

Safe Harbor Statement

This slide presentation contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital required to complete the development programs described herein, the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K/A for the year ended December 31, 2014. These forward looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward looking statements.

Investment Overview

- Oncology-focused biopharmaceutical company in Madison, WI
- Phospholipid Drug Conjugate (PDC) Delivery Platform
  - Phospholipid Ether cancer-targeting vehicle
  - Enables delivery of diverse oncologic payloads
  - Increases payload therapeutic window
- Pipeline of PDC cancer therapeutics and diagnostics
- Focused plan to unlock PDC Delivery Platform value
  - Advance CLR 131 therapeutic franchise
  - Develop early-stage chemotherapeutic conjugates
  - Expand PDC pipeline through collaborations

Phospholipid Ether Cancer-Targeting Vehicle

- Proprietary small-molecule
- Highly selective cancer and CSC targeting
- Uptake and prolonged retention in malignant cells
  - POC in broad range of cancers
- Ability to attach diverse oncologic payloads
- Extensive research and peer reviewed scientific validation



6/2014



2/2015

Basis for PDC Delivery Platform

PDC Cancer-Targeting Validation in Broad Range of Cancers

In Vitro Mechanistic POC

- Lipid Raft Uptake
- Cytoplasm & Cell Organelle Delivery
- Prolonged Retention



In Vivo POC

- 60+ Cancer & CSC Models
- Therapeutics & Imaging



In Human Data

- 70+ Patients
- 10+ Cancer Types



Demonstrated Clinical Translation

PDC Diverse Payload Delivery Validation

Radioisotopes for Cancer Therapy
- CLR 131: Multiple Myeloma
- Iodine-125



Radioisotopes for Cancer Imaging
- CLR 124: Glioma
- Iodine-123



Fluorophores for Imaging-Guided Surgery
- CLR 1502: Optical Imaging
- CLR 1501

Chemotherapeutics for Cancer Therapy
- CLR 1603-PTX: Paclitaxel
- CLR CTX Development Program



Other Payloads
- Product development and commercialization collaborations

PDC Delivery Platform Overview

Phospholipid Drug Conjugate



Enabling Targeted Delivery of Diverse Oncologic Payloads

PDC Cancer-Targeting and Payload Delivery

Phospholipid Drug Conjugates
(PDCs)

Antibody-Drug Conjugates
(ADCs)



Targeting: Lipid rafts
Delivery: Cell cytoplasm
Cancer stem cells

Targeting: Tumor-specific antigens
Delivery: Cell surface

CELLECTAR BIOSCIENCES

PDC Delivery Platform Summary

DELIVERY PLATFORM	PDC	ADC
Description	PLE: Small-Molecule	Antibody: Biologic
Manufacturing Cost/Complexity	Low	High
Cancer Targeting	Cancer Selective	Antigen Selective
--Cancer Stem Cell	Yes	?
-- Brain Metastases	Yes	?
Targeting Mechanism	Membrane-Lipid Rafts	Membrane-Antigen
Payload Delivery	Cytoplasm/Cell Organelle	Linker/Payload Dependent
Retention	Prolonged	Linker/Payload Dependent
Linker Options	Simple	Complex
Payload Diversity	Multiple	Multiple

PDCs Represent a New Class of Cancer Targeting & Payload Delivery

PDC Product Development Pipeline



* The development of CLR 125 is fully funded by a NCI Phase I/II Fast-Track SBIR research grant award
PTX = paclitaxel; GEM = gemcitabine; GEL = geldanamycin

CLR 131: Lead PDC Radiotherapeutic Product

- Payload: Iodine-131
  - Cytotoxic radioisotope
  - Thyroid cancer Tx
- PDC: CLR 131
  - Targeted cytotoxic delivery
  - Tumor uptake, retention and efficacy demonstrated in human (N=23)
    - Liquid and solid tumors
  - Solid tumor MTD established and activity observed
  - Indications beyond thyroid cancer Tx
    - Multiple Myeloma, other cancers



Opportunity for Expanded Oncology Indications

CLR 131: Clinical Rationale For Multiple Myeloma

- Multiple Myeloma
  - Incurable hematologic cancer – Orphan Designation
  - Unmet need in relapsed/refractory setting
  - Patient Demographics
  - Quantitative response criteria
    - M-protein marker
    - Free Light Chain (FLC)
- CLR 131
  - Established radiosensitivity
  - In vivo MM cell uptake – imaging validation
  - Novel mechanism of action
  - Single dose treatment

CLR 131: Clinical/Regulatory Rationale For Multiple Myeloma





- Regulatory pathway
  - Orphan designation granted
  - Potential for fast track, breakthrough therapy, accelerated approval

CLR 131: Phase 1 Multiple Myeloma Study Overview

- Multi-center, open label, dose escalation trial initiated Q2 2015
- Relapsed or refractory patients
- Primary objective:
  - Characterize safety & tolerability
- Secondary objectives:
  - Establish phase II dose
  - Assess therapeutic activity
- First cohort dosed @ 12.5 mCi/m^2
- 85 day post dose study duration
  - Safety monitoring

CLR 131: Cohort #1 Patient Performance

Treated Patients	Prior Treatment	Age	AE's	Disease Assessment[1]	Stable Disease Duration
1	12 Systemic Regimens	55	Flushing 1 Anemia 3	Stable	43 Days
2	3 Systemic Regimens 1 Radiation Treatment	74	None	Not Assessed	N/A
3	3 Systemic Regimens	70	Nausea 1 Sinus Brady 1 Lymphopenia 3 Headache 1	Stable	85+ Days
4	3 Systemic Regimens Autologous SCT	76	Hypophosphatemia 3	Stable	22 Days
5	3 Systemic Regimens	67	Decreased WBC 2 Decreased Platelet 3	Stable	85+ Days

1. International Myeloma Workshop Group (IMWG) Criteria

CLR 131: Cohort #1 Patient Performance



CELLECTAR BIOSCIENCES

Patient #3 Patient #5

CLR 131: Market Rationale for Multiple Myeloma

- Unmet need remains in the relapsed or refractory setting
- 2nd most common hematologic cancer
  - Prevalence ~ 90,000
  - Incidence ~ 26,850
  - Relapsed/Refractory ~ 13,000
- Global MM drug market
  - 2014-2019 5-8.5% CAGR
- Premium pricing for marketed products
  - $55k - $150k+

"Judging by the results of the first cohort, I believe there is significant potential for CLR 131 as a safe and tolerable treatment modality for relapsed or refractory multiple myeloma," stated Sikander Ailawadhi, MD, senior associate consultant, Division of Hematology/Oncology, Department of Medicine, The Mayo Clinic, Jacksonville, Florida, and the site's lead investigator.

Cohort #2 Initiated at 18.75 mCi/m^2; a 50% Dose Increase

CLR 125: Pre-Clinical PDC Radiotherapeutic Product

- Payload: Iodine-125
  - Cytotoxic radioisotope
  - Prostate brachytherapy Tx
- PDC: CLR 125
  - Targeted cytotoxic delivery
  - Micrometastatic disease
    - Uniquely efficacious
  - Lower hematological toxicity
- Development
  - Funded by a $2.3M NCI SBIR grant
  - Small /disseminated tumors and micrometastatic disease



NCI Funded Research Collaboration to Assess CLR 125 Clinical Applications

PDC Chemotherapeutic Program Overview

- Objective
  - Develop chemotherapy PDCs with improved efficacy & tolerability
- Clinical rationale
  - Chemotherapeutics highly effective, yet highly toxic drugs
  - Improve drug therapeutic index through targeted delivery
  - Cancer stem cell delivery – increased durability
- Business rationale
  - Many failed, pre-clinical, clinical and on market chemo's
  - New products, new patent life & life cycle management
  - Reduced regulatory hurdles

Creating Opportunities for Clinical Development Partnerships

PDC Chemotherapeutic Program Progress

- Initial chemotherapeutic payload candidates
  - PTX, SAHA, GEM, GEL, MER
- PDCs synthesized
  - Four different payloads, multiple linkers and analogs
- In vitro studies
  - 12 tumor cell lines
  - Multiple PTX and GEL PDC analogs
  - Documented stability and cytotoxic activity
- Lead PDC selected for *in vivo* targeted delivery studies
  - CLR 1603-PTX
- PDC targeted delivery assessment toolkit in development
  - Efficient, cost-effective payload analysis

CLR 1603-PTX: Pre-Clinical PDC Chemotherapeutic

- Payload: Paclitaxel
  - Well characterized chemotherapeutic
  - Breast, lung and ovarian cancers
- PDC: CLR 1603-PTX
  - Established linker and conjugation
  - Lead PDC for R&D model
    - Future PDCs, new CTX payloads
    - Process for targeted delivery assessment
- Next steps
  - In vivo pre-clinical data update – Q2 2016



Expanding Therapeutic Index

Pierre Fabre PDC Collaboration

- Announced December 2015
- Objectives
  - Co-design library of PDCs
  - Conduct *in vivo* POC studies
  - Evaluate therapeutic index vs. untargeted payloads
- Pierre Fabre to provide payloads
  - Proprietary natural product-derived cytotoxics
- Cellectar to lead conjugation and POC studies

"We are convinced that Cellectar's proprietary technology will provide our cytotoxic molecules with tissue specificity and enhanced safety which are typically lacking with untargeted agents."

- Laurent Audoly, Head of R&D of Pierre Fabre Pharmaceuticals (Dec., 2015)

Company Milestones

Q3 2015 - Present		Present - Q3 2016	
☑	Introduced PDC Delivery Platform -Therapeutic Focus -CTX Program -Collaboration Model	Pierre Fabre Collaboration Update	TBA
☑	$3.3M Financing	CTX Program Update	Q2
☑	$2.3M NCI Fast Track Grant - CLR 125 Study Initiated	CTX Patent Conversion	Q2
☑	CTX Patent Application Conversion	Phase 1 NCI Fast Track Grant Completed	Q2
☑	Pierre Fabre Collaboration	MM Study Cohort #2 Update	Q3
☑	Positive Phase 1 MM Data	MM Study Cohort #3 Initiation	Q3

Financial Summary

Capitalization

Common Stock Outstanding	**8,581,405**
Warrants (exercisable: $2.20-$25.00)	8,613,137
Options	723,933
Fully Diluted	**17,918,475**

$2.5 M cash at September 30, 2015
$2.9 M cash raised on October 1, 2015

$5.4 M cash at October 1, 2015

Company Leadership

Management	
Jim Caruso President, CEO and Director	HIP Innovation Technology- EVP & COO; Allos Therapeutics- EVP & CCO; BCI, Novartis, BASF, BMS
Jamey Weichert, PhD Company Founder, CSO, and Director	University of Wisconsin Associate Professor of the Departments of Radiology, Medical Physics, Pharmaceutics and member of the Comprehensive Cancer Center
J. Patrick Genn VP, Business Development	Continuum Investment Holdings- President; Wells Fargo-Executive
Chad Kolean CFO	Pioneer Surgical Technology- CFO; TomoTherapy – Corporate Controller
Kevin Kozak, MD, PhD CMO	Mercy Regional Cancer Center - Director of Radiation Oncology; Co-D Therapeutics- Co-Founder

Board of Directors	
Paul L. Berns Chairman of the Board of Directors	Anacor Pharmaceuticals- President and CEO; Allos Therapeutics- President and CEO; BCI, Abbott, BASF, BMS
Jim Caruso President, CEO and Director	HIP Innovation Technology- EVP & COO; Allos Therapeutics- EVP & CCO; BCI, Novartis, BASF, BMS
Stephen A. Hill, B.M. B.Ch., M.A., F.R.C.S Director	Faraday Pharmaceuticals- CEO; Targacept- President and CEO; Solvay Pharmaceuticals- President and CEO; ArQule, F. Hoffmann- La Roche Ltd.
Stefan Loren, PhD Director	Loren Capital Strategy- Founder; Westwicke Partners- Head of Life Science Practice; Perceptive Advisors, Legg Mason
John Neis Director	Venture Investors, LLC; Managing Director, Head of Healthcare Practice
Jamey Weichert, PhD Company Founder, CSO, and Director	University of Wisconsin Associate Professor of the Departments of Radiology, Medical Physics, Pharmaceutics and member of the Comprehensive Cancer Center

Investment Overview

- Oncology-focused biopharmaceutical company in Madison, WI
- Phospholipid Drug Conjugate (PDC) Delivery Platform
  - Phospholipid Ether cancer-targeting vehicle
  - Enables delivery of diverse oncologic payloads
  - Increases payload therapeutic window
- Pipeline of PDC cancer therapeutics and diagnostics
- Focused plan to unlock PDC Delivery Platform value
  - Advance CLR 131 therapeutic franchise
  - Develop early-stage chemotherapeutic conjugates
  - Expand PDC pipeline through collaborations

Appendix

Intellectual Property Portfolio

Patent / Asset	Composition of Matter	Methods of Use	Methods of Manufacturing	Freedom to Operate
CLR 131	12/2016 Orphan Drug- Multiple Myeloma	2025 -Cancer, Solid Tumors 2030 -Cancer Stem Cell	2028	✓
CLR 125	12/2016 Orphan Drug- TBD	2025 -Cancer, Solid Tumors 2030 -Cancer Stem Cell	2028	✓
CLR 124	12/2016 Orphan Drug-Glioma	2025 -Cancer Tx	2028	✓
CLR 1502	2029	2029	2029	✓
Phospholipid Ethers (various)	12/2016 - 2028	2028	2028	✓

Over 28 Patents Issued or Pending

CLR 1502: Phase I PDC Cancer Diagnostic Product

- Payload: Fluorophore
  - Fluorescent dye: Assess tissue perfusion
- PDC: CLR 1502
  - Cancer surgery imaging agent
  - Accurate visualization of tumor margins
- Breast cancer/lumpectomy
  - Complete malignant tissue removal
  - Improved patient outcomes & QOL
  - Limit repeat surgeries
  - Healthcare system savings
- Next steps
  - Identify optimal clinical development pathway
  - Assess future cancer surgery indications



Evaluating Value-Optimizing Pathways

CLR 124: Phase II PDC Cancer Diagnostic Product

- Payload: Iodine-124
  - PET/CT imaging isotope
  - Limited cancer use
- PDC: CLR 124
  - More precise cancer imaging diagnostic
  - Early detection, staging, monitoring
  - Prostate, colorectal, head & neck, other
  - Brain cancer, glioma & metastases
- Next steps
  - NCI, ICTR (brain metastases/cancer)
  - Phase II glioma data- collate & assess



Evaluating Value-Optimizing Pathways